Meloxicam does not appear to raise blood sugar. In animal studies, meloxicam had no significant effect on blood glucose, insulin, or lipid levels. The FDA prescribing information for meloxicam does not list hyperglycemia, hypoglycemia, or any change in blood sugar as an adverse reaction.
What the Research Shows
The concern makes sense. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that works by blocking an enzyme called COX-2, which drives inflammation. Since inflammation and blood sugar regulation share some overlapping biology, it’s reasonable to wonder whether suppressing one affects the other.
The available evidence is reassuring. A study on diabetic rats found that meloxicam improved cognitive problems caused by diabetes but did not significantly influence blood glucose, lipid levels, or insulin. In another study looking at meloxicam’s effects during chronic arthritis-related inflammation, researchers measured insulin levels and found that meloxicam did not change them. Meloxicam did restore levels of adiponectin, a hormone involved in how the body processes carbohydrates and fats, but this change didn’t translate into altered blood sugar readings.
It’s Not Listed as a Side Effect
The FDA’s prescribing information for meloxicam lists the most common adverse reactions as constipation, elevated liver enzymes, and anemia. Under metabolic effects, the label mentions low potassium and low magnesium. High blood sugar, low blood sugar, and worsening diabetes are not mentioned anywhere in the adverse reactions section. This is notable because the FDA requires drugmakers to report metabolic side effects when they occur at meaningful rates during clinical trials.
How Meloxicam Differs From Steroids
Part of why this question comes up is confusion between NSAIDs like meloxicam and corticosteroids like prednisone. Both reduce inflammation, but they work through completely different mechanisms. Corticosteroids are well known for spiking blood sugar, sometimes dramatically, because they cause the liver to release more glucose and make cells less responsive to insulin. Meloxicam does neither of these things. It targets a much narrower inflammatory pathway and leaves glucose metabolism largely untouched.
What Diabetic Patients Should Know
If you have diabetes and take meloxicam, blood sugar isn’t the primary concern. The real risks to watch for are kidney-related. All NSAIDs can reduce blood flow to the kidneys, and since diabetes already puts extra stress on kidney function, the combination deserves attention. That said, a population-based study found that the association between meloxicam use and chronic kidney disease was not significantly modified by the presence of diabetes. In other words, having diabetes didn’t make meloxicam notably riskier for kidney outcomes compared to people without diabetes.
Where meloxicam could indirectly affect diabetes management is through kidney function over time. Your kidneys play a role in clearing both glucose and diabetes medications from your body. If kidney function declines for any reason, the way your body handles both sugar and medication can shift. This isn’t a direct blood sugar effect of meloxicam, but it’s a practical consideration for long-term use.
Interactions With Diabetes Medications
NSAIDs as a class have a known interaction with a type of diabetes medication called sulfonylureas (these are pills that stimulate your pancreas to release more insulin). NSAIDs can sometimes increase the blood-sugar-lowering effect of sulfonylureas, which could theoretically push blood sugar too low rather than too high. This interaction is generally mild with meloxicam, but if you’re taking a sulfonylurea and notice unusual dips in blood sugar after starting meloxicam, that combination could be the reason.
For people on metformin, the interaction is different. Because NSAIDs can affect kidney function, and metformin is cleared through the kidneys, reduced kidney performance could allow metformin to build up in the body. This doesn’t change blood sugar directly, but it can increase the risk of a rare side effect of metformin called lactic acidosis. Again, this is a kidney-mediated concern, not a direct glucose effect from meloxicam itself.